Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pramlintide for Prevention of Weight Gain in Early Onset Type 1 Diabetes
NCT00505882Phase 4Withdrawn
- Sponsor
- UT Southwestern Medical Center
- Start
- Jul 2007
- Primary completion
- Dec 2008
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of pramlintide in type 1 diabetes mellitus (T1D) (2 arms), sponsored by UT Southwestern Medical Center. Primary endpoint: Change in weight at 6 months. Planned start Jul 2007; status: withdrawn.
02
Drugs
pramlintide
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT00505882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00505882.